Last reviewed · How we verify
When to Apply to Which Patient in MSC?
Mesenchymal stem cell (MSC) therapy is among the promising treatments for acute respiratory distress syndrome (ARDS). Our study aimed to investigate the clinical efficacy of MSC treatment in COVID-19 patients, to determine when this treatment can be applied to which patient, and to evaluate its contribution to prognosis.
Details
| Lead sponsor | Trabzon Kanuni Education and Research Hospital |
|---|---|
| Status | UNKNOWN |
| Enrolment | 1 |
| Start date | Sat Jan 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Mar 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- COVID-19 Acute Respiratory Distress Syndrome
Interventions
- Mesenchymal Stem Cell Antigen-1, Human
Countries
Turkey (Türkiye)